Scientists identify key protein in the inflammatory pathway driving fatty liver disease

SINGAPORE – Scientists at the Agency for Science, Technology and Research (A*STAR) and the Shanghai Institute of Immunology (SII), along with their international collaborators, have dissected the key signalling mechanism driving inflammation in metabolic dysfunction-associated steatohepatitis (MASH), through which they have also uncovered a promising new protein target to combat the fatty liver disease.

With a 5.9% prevalence in Singapore that is projected to grow to 7.5% in 2030 [1], MASH is a chronic and progressive type of fatty liver disease in which fat build-up in the liver triggers immune cells to accumulate and react, causing inflammation. Further implicated by other rising metabolic disorders (such as obesity and type 2 diabetes) as risk factors, it is one of the leading causes of liver-related morbidity and mortality, with no approved treatments currently available to halt its progression.

In their paper published in Immunity, Dr Florent Ginhoux, Joint Senior Principal Investigator at A*STAR Singapore Immunology Network (A*STAR SIgN), with his team there and at SII, as well as their collaborators, used advanced single-cell RNA sequencing, lineage tracing and mouse models to identify that the Notch signalling pathway controls the conversion of monocytes into inflammatory macrophages, a process critical to MASH development. Taking control of this pathway through the Recombination signal binding protein for immunoglobulin kappa J region (Rbpj) protein, the scientists were able to reroute the production of these inflammatory macrophages to protective monocytes instead.

Shifting the gears of immunity from inflammation to protection

The liver has its own native population of immune cells that stick to the endothelial cells surrounding the liver capillaries. Together, they act as the gatekeepers of immunity, filtering or scavenging harmful microorganisms, dead debris and lipids (fats) from incoming blood. However, when there are too many lipids, the environment turns toxic, killing the native immune cells and stressing the endothelial cells to trigger inflammatory response. The scientists found how this summons non-native monocytes to the liver, and how Notch signalling transforms them into inflammatory macrophages.

Probing deeper, the scientists discovered as well that removing Rbpj, a seminal protein in the Notch pathway, not only blocks those non-native monocytes from turning into inflammatory macrophages, but also allows them to transform into protective monocytes instead. These protective monocytes possess more lipid-scavenging receptors and can take up more lipids, thereby helping to protect the endothelial cells and quell inflammation.

A unique, dual-functioning therapeutic target

This distinctive, dual function of Rbpj makes it a key therapeutic target in inventing new reparative strategies for MASH. Applying a simple treatment of nanoparticles carrying Rbpj inhibitors was able to successfully retard inflammation and lower the grade of the MASH, proving to be an extremely effective and targeted solution with no side-effects.

“The Notch signalling pathway, and the immune cells involved, is not only well-conserved across species, but also across organs and inflammatory diseases,” said Dr Florent Ginhoux. “With this knowledge, we are interested in applying this study and treatment to other tissues and diseases with inflammatory pathways as the next step of our research.”

This highly-conserved nature of the Notch signalling pathway also presents an optimistic outlook for clinical testing, as there is a good chance that successful treatments in mice can be efficaciously applied to human patients.

Current treatments are primarily focused on metabolic mediation, but by targeting Rbpj in the Notch signalling pathway, there is hope that a new class of therapies directly addressing the underlying drivers of MASH could be made available.

[1] Estes, C., Chan, H. L., Chien, R. N., Chuang, W. L., Fung, J., Goh, G. B. B., ... & Razavi, H. (2020). Modelling NAFLD disease burden in four Asian regions—2019‐2030. Alimentary pharmacology & therapeutics, 51(8), 801-811.

For media queries and clarifications, please contact:

Tay Shu Chian
Manager, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 9726 3652
Email: tay_shu_chian@hq.a-star.edu.sg

______________________________________________________________________

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR’s R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

Follow us on

Facebook | LinkedIn | Instagram | YouTube | TikTok